Health Home > Cancer & Chemotherapy > Grade of prostate cancer

Grade of prostate cancer

Healthwise
By Bets Davis, MFA

Did you find this helpful?

Rate this article:
100% of users found this article helpful.

The grade of prostate cancer refers to how the cancer cells look under a microscope. Identifying what grade your cancer is helps you and your doctor choose the best way to treat it.

Prostate cancer cells are either well-differentiated, moderately differentiated, or poorly differentiated. Differentiation is a term that is used to describe how different the cancer cells look from normal cells under a microscope. Well-differentiated cancers have very clear boundaries and cells that look relatively normal. They usually do not grow and spread rapidly. Poorly differentiated cancers have less clearly defined boundaries and cells that look very abnormal. They often grow and spread rapidly.

After your cancer has been looked at under a microscope, your doctor can tell you what grade your cancer is.

Gleason score

Prostate cancer is often graded using the Gleason score, on a scale of 2 to 10. The Gleason score is considered a powerful tool for predicting how aggressive a tumor will be.1 The higher the Gleason score, the more likely the tumor is to grow rapidly and spread (metastasize) to other parts of the body.

  • A Gleason score of 2 to 6 indicates well-differentiated tumors with cells that are expected to grow slowly and not spread readily.
  • A Gleason score of 7 indicates moderately differentiated tumor cells.
  • A Gleason score of 8 to 10 indicates poorly differentiated tumors with cells that are likely to grow rapidly and spread to other parts of the body.

Rarely, the following system is used to grade cancer:

  • GX: Grade cannot be determined
  • G1: Well-formed, normal cells (Gleason score 2 to 4)
  • G2: Mostly normal cells (Gleason score 5 to 7)
  • G3: Poorly formed cells with many traits of cancer cells (Gleason score 8 to 10)

References

Citations

  1. DeMarzo AM, et al. (2003). Pathological and molecular aspects of prostate cancer. Lancet, 361(9361): 955–964.

Credits

Author Bets Davis, MFA
Editor Maria Essig
Editor Susan Van Houten, RN, BSN, MBA
Associate Editor Pat Truman, MATC
Primary Medical Reviewer E. Gregory Thompson, MD - Internal Medicine
Specialist Medical Reviewer Christopher G. Wood, MD, FACS - Urology/Oncology
Last Updated June 27, 2008
Last Updated: 06/27/2008

Health Resources

help

Featured Expert

Yahoo! Experts share their tips and advice

Breast Cancer Chronicles

By Lillie Shockney, R.N., M.A.S.

See All Yahoo Experts »

Yahoo! Health Groups

Join the Conversation

Join a Yahoo! Group and discuss with other memebers in the group. Share tips and experiences

See All Yahoo Groups »

Tip of the Day

Provided by: RealAgeDec 4, 2009

Finding it hard to squeeze in your workout or your walk this time of year? Don't sweat it. Sometimes, less still cuts the mustard.

Read More »

View All Tips »